Aberrant Expression of the miR-181b/miR-222 after Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
Mahdiyar Iravani SaadiMani Ramzi

Abstract

Recently, dysregulated expression of various micro RNAs has been reported in hematologic malignancies, especially AML disease which affects normal hematopoiesis in these patients and thereby contribute to clinical outcome of AML patients, associated with either poor or favorable prognosis. Herein, we evaluated the expression of miR-181b and miR-222 in acute myeloid leukemia patients and correlation with response to therapy after hematopoietic stem cell transplantation. Eighty newly diagnosed AML patients and 80 healthy controls were recruited. The expression of miR-181b and miR-222 was evaluated by real-time SYBR Green PCR method. miR-181b gene expression was significantly increased (4.7 fold) whereas miR-222 was decreased (18.3 fold) in AML patients compared to controls (P = 0.03 and P < 0.001, respectively). Both miR-181b and miR-222 were not associated with response to treatment (P > 0.05). Also, miR-181b and miR-222 were not differentially expressed in AML patients with M3 compared to non-M3 FAB subtypes (P > 0.05). miR-181b and miR-222 are aberrantly expressed in AML patients and their baseline level is not associated with response to treatment.

References

Dec 6, 2003·Science·Chang-Zheng ChenDavid P Bartel
Jan 5, 2008·British Journal of Haematology·Fabienne IskenCarsten Müller-Tidow
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
Sep 25, 2009·Human Molecular Genetics·Nilva K CervigneSuzanne Kamel-Reid
Apr 29, 2010·Current Hematologic Malignancy Reports·Guido MarcucciClara D Bloomfield
Jul 3, 2010·Science China. Life Sciences·Hong ChenYan Mi
Nov 4, 2010·Blood·Guido MarcucciClara D Bloomfield
Nov 16, 2010·Neoplasia : an International Journal for Oncology Research·Matteo BrioschiAlessandro Beghini
Nov 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian SchwindClara D Bloomfield
Apr 30, 2013·Acta Pharmacologica Sinica·Haoran Li, Burton B Yang
Jul 31, 2013·BMC Cancer·Anna RommerRotraud Wieser
Apr 22, 2014·Experimental Hematology·Velizar Shivarov, Lars Bullinger
Dec 6, 2014·Frontiers in Genetics·Mona KhalajChristopher Y Park
Feb 18, 2015·Cancer Genetics·Hengyou WengJianjun Chen
Apr 23, 2015·Annals of Hematology·Ciprian TomuleasaHermann Einsele
May 18, 2016·Molecular Cancer·Chien-Hung YehChristophe Nicot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.